Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

A recent study linked GLP-1 (glucagon-like peptide-1) agonists — the class of drugs that includes semaglutides — to an increased risk of hair loss. Here's what you should know.

New research suggests that semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy, might protect against dementia.

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared to those on other medications.

Semaglutide was initiated at a dose of 0.25 mg once weekly, and the dose was increased every 4 weeks in accordance with recommended dosing (from 0.25 mg to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg ...

Cagrilintide–semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo. (Funded by Novo Nordisk; REDEFINE 1 ...